Ischemic stroke in congenital (type II C) defective antithrombin III

Research output: Contribution to journalArticlepeer-review


Type II C is a subtype of defective antithrombin III deficiency in which there is a molecular defect in the heparin binding site. Usually, heterozygous patients with this defect have little or no thrombotic symptoms. Ischemic stroke has never been described. We report the case of a young woman who had an episode of right-sided hemiparesis. The computed tomographic scan showed an ischemic lesion in the left hemisphere. There were no previous thrombotic episodes in the patient's history and the sole risk factor for thrombosis was taking of an oral contraceptive. Her family history was mildly positive for thrombosis (superficial thrombophlebitis in two relatives). Laboratory tests showed normal antithrombin III antigen, low heparin cofactor activity and an increased slow-moving peak in crossed-immunoelectrophoresis with heparin. The same pattern was found in 7 of 20 relatives. Thus, a diagnosis of congenital type II C defective antithrombin III was made. This report suggests that young patients with ischemic stroke should be screened for defective antithrombin III.

Original languageEnglish
Pages (from-to)212-214
Number of pages3
JournalInternational Journal of Clinical & Laboratory Research
Issue number1-4
Publication statusPublished - Dec 1993


  • Antithrombin III
  • Cerebral ischemia
  • Oral contraceptives

ASJC Scopus subject areas

  • Clinical Biochemistry


Dive into the research topics of 'Ischemic stroke in congenital (type II C) defective antithrombin III'. Together they form a unique fingerprint.

Cite this